Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non–V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team
暂无分享,去创建一个
Aleksandar Sekulic | Jeffrey M Trent | Sally Hunsberger | Winnie S. Liang | David W Craig | John D Carpten | J. Carpten | J. Trent | D. Craig | B. Redman | J. Sosman | A. Bryce | P. LoRusso | W. Liang | G. Schwartz | P. Chapman | L. Fecher | S. Markovic | A. Sekulic | R. Joseph | S. Hunsberger | J. Kiefer | S. Boerner | M. Pilat | Winnie S Liang | Gary K Schwartz | Paul B Chapman | Karen M Forman | Patricia M LoRusso | Scott A Boerner | Mary Jo Pilat | Clarice Y Zuccaro | Jeffrey A Kiefer | Bruce G Redman | Svetomir N Markovic | Alan H Bryce | Richard W Joseph | C Lance Cowey | Leslie Anne Fecher | Jeffrey Alan Sosman | C. L. Cowey | K. Forman | Clarice Zuccaro | Patricia LoRusso | C. Cowey | Karen Forman | Jeff Kiefer | Winnie S. Liang
[1] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[2] Theresa Zhang,et al. Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.
[3] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[4] J. Wolchok,et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Wolchok,et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Sosman,et al. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity. , 2014 .
[7] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[8] F. André,et al. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? , 2014, The Journal of pathology.
[9] P. Stephens,et al. BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition , 2013, Clinical Cancer Research.
[10] Winnie S. Liang,et al. A Pilot Study Using Next-Generation Sequencing in Advanced Cancers: Feasibility and Challenges , 2013, PloS one.
[11] Levi A Garraway,et al. Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. Berking,et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. , 2013, The Lancet. Oncology.
[13] Razelle Kurzrock,et al. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.
[14] A. Sivachenko,et al. A Landscape of Driver Mutations in Melanoma , 2012, Cell.
[15] Matthew J. Davis,et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.
[16] William Pao,et al. Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials , 2012, PloS one.
[17] T. Fennell,et al. Melanoma genome sequencing reveals frequent PREX2 mutations , 2012, Nature.
[18] M. Herlyn. New dream team for melanoma therapy , 2012, Pigment Cell & Melanoma Research.
[19] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[20] C. Robert,et al. New drugs in melanoma: it's a whole new world. , 2011, European journal of cancer.
[21] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[22] R. Scolyer,et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site , 2011, Pigment cell & melanoma research.
[23] G. Mann,et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Michael Bittner,et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[26] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[27] R. Kurzrock,et al. Cancer: the road to Amiens. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[29] David S. Wishart,et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..
[30] H. Heng. Cancer genome sequencing: the challenges ahead. , 2007, BioEssays : news and reviews in molecular, cellular and developmental biology.
[31] Sieger Leenstra,et al. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. , 2007, Cancer research.
[32] R. Kurzrock,et al. Uncommon tumors and exceptional therapies: paradox or paradigm? , 2007, Molecular Cancer Therapeutics.
[33] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[34] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[35] G. Batist,et al. Use of statins and the risk of death in patients with prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.